We present a case of a 64-year-old man who was diagnosed with a primary anaplastic large cell lymphoma of the central nervous system (PCNSAL). He had received radical chemotherapy and radiotherapy for a non-small cell lung cancer (NSCLC) in the past. There is no known association between NSCLC and PCNSAL. We describe the diagnostic and therapeutic challenges associated with these rare intracranial lymphomas and highlight the potential role of newer biological agents in patients with anaplastic lymphoma kinase (ALK-1) positive PCNSAL.
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Case Presentation
A 64-year-old male presented with a 1-month history of progressively worsening headaches. He had no other central neurological symptoms, including ocular symptoms, and examination of the central and peripheral nervous system was normal. Physical examination did not reveal lymphadenopathy or organomegaly and was normal for all systems examined. No constitutional symptoms such as fever, weight loss or night sweats were present. Four years prior to this, he was diagnosed with a lung cancer through cytomorphology, with no immunocytochemistry being available due to the paucity of cells following a computed tomography 1 In the largest case series of nine PCNSAL cases, a bimodal distribution was suggested, with six patients being less than 22 years of age and three patients being over 46 years of age. 2 The most common presenting symptoms are focal neurological deficits, neuropsychiatric disorders, signs of raised intracranial pressure and seizures. 3 B symptoms are uncommon. 3 Radiological differential diagnoses include other malignant ICSOLs, such as glioblastomamultiforme, metastatic brain lesions and benign lesions, such as demyelinating diseases, infectious or parasitic conditions. 4 Intracranial lymphoma is often an unexpected diagnosis following a brain tumour resection or biopsy. MRI is the imaging modality of choice when PCNSL is suspected. Lesions appear iso-intense to hypointense on T2-weighted MRI, often with surrounding oedema. 5 CTguided biopsy is recommended to confirm the diagnosis of PCNSL. It is recommended that steroids are interrupted for at least 7 to 10 days before the biopsy as they can interfere with the histopathological diagnosis. 6 Complete tumour resection is rarely necessary as it has not been associated with improved survival benefit. 2 Most ALCL express T cell antigens and the less common 'null cell' variants often have genetic evidence of T cell origin. 8 The majority of ALCL (70-75 %) have detectable anaplastic lymphoma kinase (ALK-1) protein expression resulting from a genetic alteration in the ALK locus on chromosome 2. 9 More specifically, there is a distinct 2:5 translocation that fuses the ALK gene on chromosome 2 and the nucleophosmin gene (NPM) of chromosome 5. 9 Although the pathogenesis of PCNSAL is not yet clear, it could be suggested that in the ALK-1 positive anaplastic lymphomas, translocation of the ALK gene is partly responsible for the neoplastic transformation. 10 There is no evidence suggesting a familial inheritance of PCNSAL. nature of the published studies. 13, 14 Ongoing large prospective trials, such as the NCT01011920 and NTR2427, should help to establish the role of additional rituximab for PCNSL treatment. 15 Unfortunately, although patients initially respond to treatment, relapse is not uncommon.
Salvage therapies, such as temozolomide or etoposide, can be used, and we also encourage the enrolment of these patients in clinical trials, wherever possible. Of increasing interest is the potential role of crizotinib, which has recently been licensed by the Food and Drug Administration (FDA) for the treatment of ALK-1 positive NSCLCs. Crizotinib was shown to have activity in peripheral ALK-1 positive anaplastic lymphomas, 16 appeared to achieve adequate CSF concentration 17 and could be a future treatment option for patients with ALK-1 positive PCNSAL. 18 Radiotherapy has been a treatment option for intracranial lymphomas for many years. Its use as consolidation treatment is advised in patients with residual disease after chemotherapy. However, for patients that achieve a complete response, there appears to be no additional benefit, particularly given the significant short-and long-term toxicities of WBRT. 19 Results from a recent phase II study published in abstract form suggest that consolidation WBRT can be deferred until relapse. 20 In this case report, PCNSAL is a second primary in a patient who has completed curative treatment for a solid tumour 2 years previously.
This case highlights the importance of tissue diagnosis and should alert oncology MDTs to consider wider differential diagnoses (DDs) in patients presenting with ICSOLs, especially where there is no evidence of extracranial disease. We also strongly advocate entering patients into clinical trials wherever possible. In patients where the PCNSAL expresses ALK-1, crizotinib may be a candidate for targeted treatment in the future. n
